

# Defocus Incorporated Multiple Segments Spectacle lenses and 0.025% atropine for myopia control in European children: 12-month results of a Randomized Clinical Trial



Poster A03

Noemi Guemes Villahoz<sup>1,3</sup>, Paula Talavero-Gonzalez<sup>1</sup>, Rafael Bella-Gala<sup>2</sup>, Paloma Porras-Angel<sup>2,3</sup>, Elena Hernandez-Garcia<sup>1</sup>, Beatriz Martin-Garcia<sup>2</sup>, Alicia Ruiz-Pomeda<sup>2</sup>, C Nunila Gomez-de-Liano<sup>2</sup>, Rakhee Shah<sup>4,5</sup>, Julian Garcia Feijoo<sup>1-3</sup>, Rosario Gomez-de-Liano<sup>1-3</sup>

**Affiliations:** 1. Ophthalmology Service, Hospital Clinico San Carlos, Madrid, Spain. 2. San Carlos Health Research Institute (IdISSC), Madrid, Spain 3. Complutense University of Madrid, Spain 4. Centre of Applied Vision Research, Optometry & Visual Sciences, City St George's, University of London. 5. HOYA Vision Care, Amsterdam, The Netherlands

noemiguemes@gmail.com

## BACKGROUND

Defocus Incorporated Multiple Segments (DIMS) spectacle lenses and atropine have proven standalone efficacy in controlling myopia progression in children.<sup>1,2</sup>

There is a scarcity of evidence of their efficacy when used in combination.<sup>3,4</sup>

**PURPOSE:** This **randomized controlled trial (RCT)** aims to evaluate and compare the **efficacy of combination treatment using 0.025% atropine and DIMS spectacle lenses** compared to **0.025% atropine and single vision (SV) lenses** in slowing myopia progression in European myopic children.

## METHODS



RCT conducted on children aged 4-16 years with myopia between -1.00 and -6.00D and astigmatism  $\leq 2.00$ D.

Random allocation:

0.025% atropine and SV lenses treatment group (group A) or 0.025% atropine and DIMS lenses treatment group (group B).

### GROUP A

### GROUP B



Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline, 6 and 12 months.

Statistical analyses (Mann-Whitney U-test or Chi-squared test) were performed to test for significance between the two groups.

## Acknowledgements

We thank the Clinical Research and Clinical Trials Unit (UICEC) of the San Carlos Health Research Institute (IdISSC) for their support in the design of the study. This study is a collaborative research project supported by HOYA Corporation. We thank Carolina Rodriguez and the rest of the HOYA lens Iberia team for the endless support with this Project. Thank you to Dr Irene Schiavetti for her support in the statistical analysis.


## RESULTS

79 patients completed the 12 month-follow-up:

**Group A:** n=38 (48.1%), 47.4% female, mean age of 9.00  $\pm$  2.74 years

**Group B:** n=41 (51.9%), 46.3% female, mean age of 9.68  $\pm$  2.65 years

No significant differences in gender (p = 0.93) or age (p = 0.26) between the groups.



## AXIAL LENGTH

At 6 months, mean AL  $\pm$ SD change was 0.08  $\pm$  0.09 mm in group A and 0.03  $\pm$  0.15 mm in group B. Group B had significantly less axial elongation than group A, with a mean difference of 0.04 (SE: 0.03)mm (95% CI -0.01 to 0.10, p=0.13).

At 12 months, mean AL  $\pm$ SD change was 0.18  $\pm$  0.13 mm in group A and 0.08  $\pm$  0.16 mm in group B. Group B had significantly less axial elongation than group A, with a mean difference of 0.10 (SE: 0.03)mm (95% CI 0.03 to 0.16, p=0.005).

**36.6% of the children in Group B had no axial elongation over 12 months, compared to 7.9% of the children in group A (p=0.002).**

## References


- Lam CSY, Tang WC, Tse DY, et al Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. *British Journal of Ophthalmology* 2020
- Lam CSY, et al. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. *Sci Rep.* 2023
- Nucci P et al. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. *PLoS One.* 2023
- Huang Z et al. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. *Sci Rep.* 2022 Dec 24;12(1):22311. doi: 10.1038/s41598-022-25599-z. Erratum in: *Sci Rep.* 2023

## RESULTS

**SER:**

At 6 months, mean SER  $\pm$ SD progression was -0.05  $\pm$  0.25 D (Group A) and 0.10  $\pm$  0.85 D (Group B), mean difference -0.16 (SE: 0.14) D (95% CI -0.3 to 0.12, p=0.27).

At 12 months, mean SER  $\pm$ SD progression was -0.16  $\pm$  0.31 D and -0.15  $\pm$  0.38 D, respectively, mean difference -0.01 (SE: 0.08) D (95% CI -0.17 to 0.14, p=0.87).



## CONCLUSIONS

**Combination treatment with 0.025% atropine and DIMS spectacle lenses is more effective in controlling axial elongation than 0.025% atropine with SV lenses in European children.**

The differences in SER between the groups were not significant.

The AL increase in group B was less than that previously reported with DIMS spectacle lenses alone in Asian and European children over 12 months.

These findings suggest that other factors, such as pupil size, may enhance the efficacy of DIMS lenses in controlling axial elongation, supporting a possible synergistic effect between the two treatments.

